BAYER AG

Orion’s partner Bayer submits EU application for darolutamide in metastatic hormone-sensitive prostate cancer, based on ARANOTE trial results.

Bayer submits application to EMA for darolutamide, an oral androgen receptor inhibitor, for use with ADT in metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide, already approved in mHSPC and nmCRPC, showed significant reduction in radiological progression or death risk in the ARANOTE trial.

Top pharma companies leverage Shanghai's innovation ecosystem; 37 new measures aim to boost early-stage clinical research and speed up new medicine launches. Bayer inaugurates life science incubator in Shanghai, while AstraZeneca elevates Shanghai to its global strategic site. Sanofi gains approval for innovative medicines in China ahead of schedule, with plans for concurrent global clinical trials.

The Global Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 18.5 billion from 2024-2028, driven by increasing disease incidence and nutritional therapies. Key players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and others. High treatment costs pose a challenge.

William Melissen, 51, awarded $78 million against Monsanto; jury found Roundup herbicide contributed to his blood cancer diagnosis in 2020. Monsanto plans to appeal, disputing the verdict.

Bayer ordered to pay $78 million to Pennsylvania man, William Melissen, in Roundup cancer trial. Jury awarded $3 million in compensatory damages and $75 million in punitive damages. Bayer disputes verdict, citing scientific evidence and regulatory assessments. Melissen claims non-Hodgkin's lymphoma from glyphosate exposure. Bayer settled most Roundup lawsuits in 2020 for $10.9 billion but faces 58,000 remaining claims.

Bayer's NDA for elinzanetant, a non-hormonal treatment for moderate-to-severe VMS associated with menopause, has been accepted by the FDA. Elinzanetant, a dual NK-1 and 3 receptor antagonist, is in late-stage clinical development and may also reduce sleep disturbances. Bayer anticipates approval to offer a new treatment option for women experiencing VMS.

The global pharmacogenomics market, valued at $7.9 billion in 2023, is projected to reach $16.1 billion by 2032, growing at a CAGR of 8.2%. Factors driving growth include the pharmaceutical industry's expansion, demand for precision medicines, and technological advancements in biomarker labeling solutions. The market is segmented by technology, application, end user, and region, with key players including Abbott Laboratories, AstraZeneca, Bayer AG, and others.

Recursion's AI platform developed REC-1245, a drug for solid tumors and lymphoma, progressing from target to preclinical candidate in under 18 months. The drug selectively degrades RBM39, offering a new therapeutic approach for resistant tumors. Industry experts note the potential of AI in speeding up drug discovery timelines, though the impact on phase transition likelihood remains uncertain.